Latham & Watkins Advises on Vir Biotechnology’s US$150 Million Public Offering of Common Stock

Vir Biotechnology (VIR) priced a public offering of 15M shares at $10 each, raising $150M. Underwriters have a 30-day option for 2.25M more shares. Closing is expected November 16, 2026. Latham & Watkins advised the underwriters.

Original reporting
Published Nov 13, 2026, 6:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 10:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Latham & Watkins Advises on Vir Biotechnology’s US$150 Million Public Offering of Common Stock — source image
Decision brief

The 30-second read

$VIRBearishHigh
01

Why it matters

The $150 M raise provides capital for pipeline advancement but introduces dilution, likely prompting a near‑term price dip.

02

Market read

Primary disclosure of a mid‑size biotech equity raise; relevant for short‑term traders and sector investors.

03

What to watch

Potential strategic partnership or pipeline milestones that could be financed by the proceeds.

Relevance 9/10Novelty 9/10Timing: today

Background

Vir Biotechnology is a clinical‑stage biopharma focused on infectious diseases and cancer. The offering is underwritten and includes an over‑allotment option.

Company-level read

Ticker impact

$VIRBearishHigh confidence
Context

Vir Biotechnology announced pricing of a $150 million public offering of 15 M shares at $10 each, with a 30‑day option for 2.25 M additional shares.

Expected impact

likely pressure as the market prices in dilution from the $150 M capital raise

Evidence & confidence

First report of a sizable primary offering; investors typically react with short‑term sell pressure.

Market effects

Adds supply to the biotech financing market, may prompt peers to reassess fundraising timing.

US biotech sector could see modest short‑term weakness.

Limited to investors focused on biotech equities and capital‑raising activity.

Counterpoint

If the raise funds a breakthrough trial, the long‑term upside could outweigh short‑term dilution concerns.

Key entities

  • Vir Biotechnology, Inc.

    Issuer of the public offering.

  • Latham & Watkins LLP

    Advised the underwriters on the transaction.

Related articles

$VIRHigh

Why Vir Biotechnology shares are trading lower today

Vir Biotechnology (VIR) shares fell 18.8% after announcing a $150M public offering of 15M shares at $10 each. The stock closed at $9.96, down 17.7% from the prior close. The company is up 68% YTD but 26.9% below its 52-week high. The offering may dilute existing shares and pressure the stock price.

$VIRHighAI 8/10

Vir Biotechnology Shares Drop as Biotech Firm Moves Ahead With Stock Sale

Vir Biotechnology (VIR) shares dropped 10% after announcing a stock sale. The company plans to sell 15 million shares at $10 each, raising $150 million. Underwriters may buy an additional 2.25 million shares, potentially increasing total proceeds to $172.5 million. The deal is expected to close on Nov. 16, 2026, subject to customary conditions and expenses.

$VIRHighAI 9/10

Vir Biotechnology stock tumbles on $150M share offering

Vir Biotechnology (NASDAQ:VIR) shares dropped 15% premarket Friday after announcing a $150M share offering at $10 per share. The company will sell 15M shares, with an option for underwriters to buy 2.25M more. Proceeds, before expenses, are expected to reach $150M. The offering is set to close November 16, 2026, subject to conditions. Leerink Partners, Morgan Stanley, and Evercore ISI are bookrunners.